The Pharmacokinetics of Zidovudine and Oxazepam Alone and in Combination in the HIV-Infected Patient
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 8
- 试验地点
- 1
研究概览
简要总结
To determine if a pharmacokinetic (blood level) interaction exists between zidovudine (AZT) and oxazepam in the HIV-infected patient. Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.
详细描述
Benzodiazepines (such as oxazepam) are among the most frequently prescribed class of drugs and are commonly used therapeutically for patients with chronic disease. This study is important because of the potential for toxicity resulting from a reaction between AZT and benzodiazepines and the likelihood of frequent use of the combination of these drugs in patients with HIV infection.
Patients are studied to determine oral and intravenous AZT and single oral dose oxazepam pharmacokinetics. Patients then take AZT and oxazepam together to determine if interactions between the drugs occur.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Concurrent Medication:
- •Stable prescribed dosage of zidovudine (AZT), = or > 500 mg/day.
- •Prophylaxis for Pneumocystis carinii pneumonia (PCP) with aerosolized pentamidine.
- •Erythropoietin.
- •Patients must be:
- •HIV positive by ELISA and Western blot.
- •Currently taking a stable prescribed dosage of 500 mg/day of zidovudine (AZT).
排除标准
- •Co-existing Condition:
- •Patients with the following conditions or symptoms are excluded:
- •Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
- •Significant underlying medical condition that could impair continuous participation in study.
- •Malabsorption syndrome (3 or more loose stools a day for at least 4 weeks associated with an unintentional weight loss of at least 10 percent of body weight).
- •Concurrent Medication:
- •Oral contraceptives.
- •Cytotoxic chemotherapy.
- •Ganciclovir.
- •Flucytosine.
- •Probenecid.
- •Valproic acid.
- •Sulfa drugs.
- •Sucralfate.
- •Rifampin.
- •Antacids within 2 hours of zidovudine (AZT) dose.
- •Isoniazid.
- •Ketoconazole.
- •Pyrimethamine.
- •Clindamycin.
- •Ibuprofen.
- •Investigational drugs not specifically allowed.
- •Patients with the following are excluded:
- •Allergy to benzodiazepines or a previously documented intolerance to zidovudine (AZT) therapy of = or < 600 mg/day.
- •Significant underlying medical condition that could impair continuous participation in study.
- •Unable to take oral medication reliably.
- •Prior Medication:
- •Excluded within 30 days of study entry:
- •Antiretroviral agents other than zidovudine (AZT).